Irbesartan Accord

Irbesartan, the active ingredient in Irbesartan Accord, is an angiotensin II receptor blocker presented as an oral tablet for systemic use. It is indicated for the management of hypertension and for protecting kidney function in patients with diabetic nephropathy, as well as for use in certain cases of heart failure in adults.

GNH USA supplies Irbesartan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch.

Irbesartan is used to treat conditions related to the renin‑angiotensin system and cardiovascular health. - Hypertension: lowers blood pressure and reduces the risk of cardiovascular events. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Heart failure: improves symptoms and may reduce hospitalisation in patients with reduced ejection fraction.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach or urge to vomit. - Hyperkalemia (mild): slight increase in serum potassium levels.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue or throat that may compromise breathing. - Severe hyperkalemia: marked elevation of potassium that can affect heart rhythm. - Acute renal impairment: sudden decline in kidney function. - Hepatic injury: signs of liver dysfunction such as jaundice. - Hypotension: significant drop in blood pressure causing faintness.

Before initiating therapy, clinicians should consider several safety aspects. - Monitor blood pressure: adjust dosage if target levels are not achieved. - Assess renal function: avoid use in patients with severe renal impairment. - Check serum potassium: risk of hyperkalemia, especially with potassium‑sparing agents. - Contraindicated in pregnancy: fetal toxicity has been reported. - Review concomitant medications: potential interactions may require dose adjustments. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Irbesartan may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Aliskiren in patients with diabetes: combined use can increase risk of renal dysfunction. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Concurrent ACE inhibitors or other ARBs: dual blockade of the renin‑angiotensin system is discouraged.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Lithium: irbesartan can raise lithium concentrations, necessitating level monitoring. - Cyclosporine: may increase irbesartan plasma levels, requiring dose evaluation.